Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-701 in mild to moderate hypertension with elevated LDL-C
CTR20260395Phase 2Active
- Sponsor
- BeBetter Med
- Start
- Mar 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BEBT-701 in essential hypertension, hypercholesterolemia, sponsored by BeBetter Med. Started Mar 2026; status: active.
02
Drugs
BEBT-701
03
Conditions
essential hypertensionhypercholesterolemia
Beyond the preview
Go deeper on CTR20260395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260395.